Anti-Von Willebrand Factor antibody (FITC) (ab8822)

Overview

  • Product nameAnti-Von Willebrand Factor antibody (FITC)
    See all Von Willebrand Factor primary antibodies
  • Description
    Sheep polyclonal to Von Willebrand Factor (FITC)
  • ConjugationFITC. Ex: 493nm, Em: 528nm
  • SpecificityThe unconjugated immunoglobulin gives no arcs when tested by immunoelectrophoresis against human serum. Identity has been confirmed by double diffusion (Ouchterlony) against von Willebrand Factor and an anti-von Willebrand Factor of known specificity.
  • Tested applicationsSuitable for: IHC-Fr, ICC/IF, Flow Cytmore details
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Full length native protein (purified) corresponding to Von Willebrand Factor. The immunogen was purified from citrated human plasma, which was>95% pure by SDS-PAGE

  • Positive control
    • Direct on frozen sections of human tonsil.

Properties

Applications

Our Abpromise guarantee covers the use of ab8822 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr 1/50 - 1/100.
ICC/IF Use at an assay dependent dilution. PubMed: 20448112
Flow Cyt Use at an assay dependent concentration. PubMed: 21050042

Target

  • FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
  • Tissue specificityPlasma.
  • Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
  • Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 4 TIL (trypsin inhibitory-like) domains.
    Contains 3 VWFA domains.
    Contains 3 VWFC domains.
    Contains 4 VWFD domains.
  • DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
  • Post-translational
    modifications
    All cysteine residues are involved in intrachain or interchain disulfide bonds.
    N- and O-glycosylated.
  • Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
  • Information by UniProt
  • Database links
  • Alternative names
    • Coagulation factor VIII antibody
    • Coagulation factor VIII VWF antibody
    • F8VWF antibody
    • Factor VIII related antigen antibody
    • von Willebrand antigen 2 antibody
    • von Willebrand antigen II antibody
    • Von Willebrand disease antibody
    • VWD antibody
    • vWF antibody
    • VWF_HUMAN antibody
    see all

References for Anti-Von Willebrand Factor antibody (FITC) (ab8822)

This product has been referenced in:
  • Kristofik N  et al. Impaired von Willebrand factor adhesion and platelet response in thrombospondin-2 knockout mice. Blood 128:1642-50 (2016). Read more (PubMed: 27471233) »
  • Ye LX  et al. Beclin 1 knockdown retards re-endothelialization and exacerbates neointimal formation via a crosstalk between autophagy and apoptosis. Atherosclerosis 237:146-154 (2014). Read more (PubMed: 25238224) »

See all 5 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (Human brain microvascular endothelial cell)
Specification Human brain microvascular endothelial cell
Fixative Paraformaldehyde
Permeabilization Yes - 1% Triton X-100
Blocking step BSA as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Username

Abcam user community

Verified customer

Submitted Aug 20 2012

Thank you for your email. Unfortunately we only have the same lot in stock, would you like a replacement from the same lot or an alternative product? We will be able to organise the replacement with Cedarlane. Looking forward to your re...

Read More

Thank you for your enquiry. We do not test this antibody for cross reactivity with Fibronectin. However as Fibronectin is a glycoprotein which binds Heparin, Integrin and Collagen like Von Willebrand factor and that the immunogen for this antibody i...

Read More

We do not routinely offer free or trial sized samples for testing purposes. Our policy at Abcam is that if an antibody does not work as specified on the datasheet, we will offer a replacement or reimbursement. Should you decide to test an antibody ...

Read More

As stated on the datasheet, this antibody has only been tested with humans. IF is the only application tested.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"